Oncolytic Virus Enables the Immune System to Attack Tumors

by Shana SpindlerOne of the most important findings in cancer research in the past two decades is that tumors can create force field-like protection against the immune system. A new study has identifi

Updated on: October 15,2023

Oncolytic Virus Enables the Immune System to Attack Tumors

by Shana SpindlerOne of the most important findings in cancer research in the past two decades is that tumors can create force field-like protection against the immune system. A new study has identifi

Updated on:October 15,2023

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on: October 24,2023

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on:October 24,2023

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13, 2022Gina MauroCYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung

Updated on: October 17,2023

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13, 2022Gina MauroCYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung

Updated on:October 17,2023

A new mechanism of drug resistance discovered for breast cancer

by Universita Cattolica del Sacro CuoreEmergence of CSCs following IFN-I treatment.a, Multiparametric flow cytometry analysis of the illustrated CSC surface markers in MCA205 and AT3 cells treat

Updated on: December 21,2023

A new mechanism of drug resistance discovered for breast cancer

by Universita Cattolica del Sacro CuoreEmergence of CSCs following IFN-I treatment.a, Multiparametric flow cytometry analysis of the illustrated CSC surface markers in MCA205 and AT3 cells treat

Updated on:December 21,2023

Adjuvant capecitabine after CRT improves survival in locally advanced nasopharynx

October 25, 2022Jason HarrisTreatment with adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival compared with observation and CRT for patients with l

Updated on: October 17,2023

Adjuvant capecitabine after CRT improves survival in locally advanced nasopharynx

October 25, 2022Jason HarrisTreatment with adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival compared with observation and CRT for patients with l

Updated on:October 17,2023

Seeking leukemia's Achilles heel

byAmerican Society for Biochemistry and Molecular BiologyGraphical abstract. Credit:Molecular & Cellular Proteomics(2023). DOI: 10.1016/j.mcpro.2023.100503A team of researchers h

Updated on: December 17,2023

Seeking leukemia's Achilles heel

byAmerican Society for Biochemistry and Molecular BiologyGraphical abstract. Credit:Molecular & Cellular Proteomics(2023). DOI: 10.1016/j.mcpro.2023.100503A team of researchers h

Updated on:December 17,2023

FDA approves CAR T cell treatment for resistant mantle cell lymphoma

by Jim Stallard,Memorial Sloan Kettering Cancer CenterCredit: Pixabay/CC0 Public DomainMantle cell lymphoma (MCL) is a rare and sometimes ruthless form of non-Hodgkin lymphoma. Even when treatme

Updated on: August 27,2024

FDA approves CAR T cell treatment for resistant mantle cell lymphoma

by Jim Stallard,Memorial Sloan Kettering Cancer CenterCredit: Pixabay/CC0 Public DomainMantle cell lymphoma (MCL) is a rare and sometimes ruthless form of non-Hodgkin lymphoma. Even when treatme

Updated on:August 27,2024

Automated detection of eye surface cancer

by ARC Centre of Excellence for Nanoscale BioPhotonicsA new automated non-invasive technique for diagnosing eye disease. Credit: ARC Centre of Excellence for Nanoscale BioPhotonicsResearchers hav

Updated on: May 25,2024

Automated detection of eye surface cancer

by ARC Centre of Excellence for Nanoscale BioPhotonicsA new automated non-invasive technique for diagnosing eye disease. Credit: ARC Centre of Excellence for Nanoscale BioPhotonicsResearchers hav

Updated on:May 25,2024

Scientists unveil chemotherapy resistance mechanism related to p53 mutation

by Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)Comparison between the response of tumoral cells to chemotherapy with no mutation of p53 (upper cells) and of mu

Updated on: December 20,2023

Scientists unveil chemotherapy resistance mechanism related to p53 mutation

by Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)Comparison between the response of tumoral cells to chemotherapy with no mutation of p53 (upper cells) and of mu

Updated on:December 20,2023

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14, 2023Caroline SeymourHigher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutio

Updated on: October 24,2023

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14, 2023Caroline SeymourHigher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutio

Updated on:October 24,2023

Novel therapeutic targets discovered for triple-negative breast cancer

by Melissa Rohman,Northwestern UniversityThe signature of TRIM21low/CD73highis associated with unfavorable immune response. (A) Proteomic data from CPTAC identified that the expression of

Updated on: December 21,2023

Novel therapeutic targets discovered for triple-negative breast cancer

by Melissa Rohman,Northwestern UniversityThe signature of TRIM21low/CD73highis associated with unfavorable immune response. (A) Proteomic data from CPTAC identified that the expression of

Updated on:December 21,2023

Cost of cancer treatment can impact health of survivors

byMedical College of Georgia at Augusta UniversityDrs. Steven Coughlin, from left, Jorge Cortes and Biplab Datta. Credit: Michael Holahan, Augusta UniversityA significant number of people who ha

Updated on: December 18,2023

Cost of cancer treatment can impact health of survivors

byMedical College of Georgia at Augusta UniversityDrs. Steven Coughlin, from left, Jorge Cortes and Biplab Datta. Credit: Michael Holahan, Augusta UniversityA significant number of people who ha

Updated on:December 18,2023